adplus-dvertising
Connect with us

Business

Oxford–AstraZeneca vaccine: What you should know, in 500 words – Aljazeera.com

Published

 on


The UK-made vaccine is cheaper than Pfizer-BioNTech and Moderna’s products, and can be stored at fridge temperature.

The Oxford-AstraZeneca COVID-19 vaccine was created by the University of Oxford and its British-Swedish pharmaceutical company partner, AstraZeneca.

Independent scientists have confirmed that the vaccine is “safe and effective” at preventing symptomatic COVID-19, according to preliminary results from its phase three trials published in The Lancet in early December.

Phase three is a large trial involving thousands of people, to prove the vaccine protects people.

The United Kingdom-made vaccine is significant because it is cheaper than the other two major shots being produced by Pfizer-BioNTech and Moderna.

Unlike its main competitors, it can be stored at a regular fridge temperature.

With the availability of more established Oxford technology, the vaccine is also easier to mass-produce and AstraZeneca has promised not to profit from it during the pandemic.

Pfizer-BioNTech’s product costs around £15 per dose ($20), Moderna’s is about £25 ($33), and the Oxford-AstraZeneca vaccine is available at a much cheaper price of around £3 ($4).

The vaccine can be stored, transported and handled for at least six months at 2-8 degrees Celsius (35-46F).

Pfizer and Moderna have a success rate of around 95 percent.

Interim data suggests the Oxford-AstraZeneca vaccine has an average efficacy of 70.4 percent, a figure which could be as high as 90 percent if the dose is adjusted.

“The results show that the vaccine is effective against COVID-19, with in particular no severe infections and no hospitalisations in the vaccine group,” said AstraZeneca Chief Executive Officer Pascal Soriot.

The efficacy rates vary because the preliminary data examined two different ways to administer the vaccine.

In one group, patients were given a placebo which consisted of a smaller initial dose of the vaccine followed by a larger booster dose one month later. Surprisingly, data analysis found that the vaccine was about 90 percent effective at preventing COVID-19 in this group.

In the second group, patients were given the same dose in both instances, producing a lower efficacy rate of 62.1 percent.

It is yet unclear why a smaller initial dose performs better. But scientists have suggested it could be because a larger initial dose prompts the body to produce antibodies against the vaccine itself.

Another reason could be that a smaller initial dose triggers memory cells, preparing the body to produce antibodies in greater amounts when the second larger dose is administered.

The Pfizer-BioNTech and Moderna vaccines are based on messenger RNA (mRNA) technology.

Oxford-AstraZeneca’s is different – it is an adenovirus-vectored vaccine taken from a common cold that normally infects chimpanzees.

Although it has been genetically modified to avoid infection in people, it carries only a part of the coronavirus called the “spike protein”.

Once the vaccine is injected into human cells, it triggers an immune response against the spike proteins, producing antibodies and memory cells which destroy infected cells.

The Medicines and Healthcare products Regulatory Authority (MHRA) in the UK now has to decide which dose to use if it approves the vaccine for emergency use.

But in India, a country badly hit, the government is accelerating its review of COVID-19 vaccines developed by Oxford-AstraZeneca and Pfizer-BioNTech.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Canada Goose to get into eyewear through deal with Marchon

Published

 on

 

TORONTO – Canada Goose Holdings Inc. says it has signed a deal that will result in the creation of its first eyewear collection.

The deal announced on Thursday by the Toronto-based luxury apparel company comes in the form of an exclusive, long-term global licensing agreement with Marchon Eyewear Inc.

The terms and value of the agreement were not disclosed, but Marchon produces eyewear for brands including Lacoste, Nike, Calvin Klein, Ferragamo, Longchamp and Zeiss.

Marchon plans to roll out both sunglasses and optical wear under the Canada Goose name next spring, starting in North America.

Canada Goose says the eyewear will be sold through optical retailers, department stores, Canada Goose shops and its website.

Canada Goose CEO Dani Reiss told The Canadian Press in August that he envisioned his company eventually expanding into eyewear and luggage.

This report by The Canadian Press was first published Sept. 19, 2024.

Companies in this story: (TSX:GOOS)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

A timeline of events in the bread price-fixing scandal

Published

 on

 

Almost seven years since news broke of an alleged conspiracy to fix the price of packaged bread across Canada, the saga isn’t over: the Competition Bureau continues to investigate the companies that may have been involved, and two class-action lawsuits continue to work their way through the courts.

Here’s a timeline of key events in the bread price-fixing case.

Oct. 31, 2017: The Competition Bureau says it’s investigating allegations of bread price-fixing and that it was granted search warrants in the case. Several grocers confirm they are co-operating in the probe.

Dec. 19, 2017: Loblaw and George Weston say they participated in an “industry-wide price-fixing arrangement” to raise the price of packaged bread. The companies say they have been co-operating in the Competition Bureau’s investigation since March 2015, when they self-reported to the bureau upon discovering anti-competitive behaviour, and are receiving immunity from prosecution. They announce they are offering $25 gift cards to customers amid the ongoing investigation into alleged bread price-fixing.

Jan. 31, 2018: In court documents, the Competition Bureau says at least $1.50 was added to the price of a loaf of bread between about 2001 and 2016.

Dec. 20, 2019: A class-action lawsuit in a Quebec court against multiple grocers and food companies is certified against a number of companies allegedly involved in bread price-fixing, including Loblaw, George Weston, Metro, Sobeys, Walmart Canada, Canada Bread and Giant Tiger (which have all denied involvement, except for Loblaw and George Weston, which later settled with the plaintiffs).

Dec. 31, 2021: A class-action lawsuit in an Ontario court covering all Canadian residents except those in Quebec who bought packaged bread from a company named in the suit is certified against roughly the same group of companies.

June 21, 2023: Bakery giant Canada Bread Co. is fined $50 million after pleading guilty to four counts of price-fixing under the Competition Act as part of the Competition Bureau’s ongoing investigation.

Oct. 25 2023: Canada Bread files a statement of defence in the Ontario class action denying participating in the alleged conspiracy and saying any anti-competitive behaviour it participated in was at the direction and to the benefit of its then-majority owner Maple Leaf Foods, which is not a defendant in the case (neither is its current owner Grupo Bimbo). Maple Leaf calls Canada Bread’s accusations “baseless.”

Dec. 20, 2023: Metro files new documents in the Ontario class action accusing Loblaw and its parent company George Weston of conspiring to implicate it in the alleged scheme, denying involvement. Sobeys has made a similar claim. The two companies deny the allegations.

July 25, 2024: Loblaw and George Weston say they agreed to pay a combined $500 million to settle both the Ontario and Quebec class-action lawsuits. Loblaw’s share of the settlement includes a $96-million credit for the gift cards it gave out years earlier.

Sept. 12, 2024: Canada Bread files new documents in Ontario court as part of the class action, claiming Maple Leaf used it as a “shield” to avoid liability in the alleged scheme. Maple Leaf was a majority shareholder of Canada Bread until 2014, and the company claims it’s liable for any price-fixing activity. Maple Leaf refutes the claims.

This report by The Canadian Press was first published Sept. 19, 2024.

Companies in this story: (TSX:L, TSX:MFI, TSX:MRU, TSX:EMP.A, TSX:WN)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

TD CEO to retire next year, takes responsibility for money laundering failures

Published

 on

 

TORONTO – TD Bank Group, which is mired in a money laundering scandal in the U.S., says chief executive Bharat Masrani will retire next year.

Masrani, who will retire officially on April 10, 2025, says the bank’s, “anti-money laundering challenges,” took place on his watch and he takes full responsibility.

The bank named Raymond Chun, TD’s group head, Canadian personal banking, as his successor.

As part of a transition plan, Chun will become chief operating officer on Nov. 1 before taking over the top job when Masrani steps down at the bank’s annual meeting next year.

TD also announced that Riaz Ahmed, group head, wholesale banking and president and CEO of TD Securities, will retire at the end of January 2025.

TD has taken billions in charges related to ongoing U.S. investigations into the failure of its anti-money laundering program.

This report by The Canadian Press was first published Sept. 19, 2024.

Companies in this story: (TSX:TD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending